Effectiveness and Safety of Reirradiation With Stereotactic Ablative Radiotherapy of Lung Cancer After a First Course of Thoracic Radiation: A Meta-analysis

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorFaculdade de Medicina de Ribeirão Preto-
Autor(es): dc.creatorViani, Gustavo A.-
Autor(es): dc.creatorArruda, Caio V. [UNESP]-
Autor(es): dc.creatorDe Fendi, Ligia I.-
Data de aceite: dc.date.accessioned2022-02-22T00:26:47Z-
Data de disponibilização: dc.date.available2022-02-22T00:26:47Z-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-08-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1097/COC.0000000000000709-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/199226-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/199226-
Descrição: dc.descriptionOBJECTIVE: The effectiveness and safety of reirradiation with stereotactic ablative radiotherapy (re-SABR) in patients with recurrence after a previous course of radiation are limited to small series. We carried out a meta-analysis to summarize existing data and identify trends in overall survival (OS), local control (LC), and toxicity after re-SABR in patients with recurrence of lung cancer. MATERIALS AND METHODS: Eligible studies were identified on Medline, Embase, the Cochrane Library, and the proceedings of annual meetings through June 2019. We followed the PRISMA and MOOSE guidelines. A meta-regression analysis was carried out to assess whether there is a relationship between moderator variables and outcomes. A P-value<0.05 was considered significant. RESULTS: Twenty observational studies with a total of 595 patients treated were included. The 2-year OS and LC were 0.54 (95% confidence interval [CI]: 0.48-0.61) and 0.73 (95% CI: 0.66-0.80), respectively. The rate of any toxicity grade ≥3 was 0.098 (95% CI: 0.06-13.6), with 9 grade 5 toxicity (1.5%). In the meta-regression, the re-SABR dose (P=0.028), tumor size (P=0.031), and time to recurrence (P=0.018) showed an association with survival. For LC, the re-SABR dose (P=0.034) and tumor size (P=0.040) were statistically significant. Any toxicity grade ≥3 showed a relationship with the cumulative dose (P=0.024). Cumulative dose ≤145 versus >145 Gy2 had 3% versus 15% (P=0.013) of any grade ≥3 toxicity. CONCLUSIONS: Re-SABR produces satisfactory LC and OS rates with an acceptable rate of toxicity. The balancing between the re-SABR dose and the tumor location has the potential to reduce severe and fatal toxicity.-
Descrição: dc.descriptionRibeirão Preto Medical School University of São Paulo-
Descrição: dc.descriptionBioscience Institute of University of State from Sao Paulo (UNESP)-
Descrição: dc.descriptionFaculdade de Medicina de Ribeirão Preto-
Descrição: dc.descriptionBioscience Institute of University of State from Sao Paulo (UNESP)-
Formato: dc.format575-581-
Idioma: dc.languageen-
Relação: dc.relationAmerican journal of clinical oncology-
???dc.source???: dc.sourceScopus-
Título: dc.titleEffectiveness and Safety of Reirradiation With Stereotactic Ablative Radiotherapy of Lung Cancer After a First Course of Thoracic Radiation: A Meta-analysis-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.